一些研究已经报道了肿瘤体积缩减比（VRR）对非小细胞肺癌患者放射治疗（RT）的潜在预后意义。然而，目前尚无关于体积缩减与小细胞肺癌（SCLC）患者预后意义的数据。本研究旨在证明肿瘤体积缩减比与治疗效果之间的相关性。该研究纳入了2013年至2020年期间在我们机构接受分段放射治疗的61名SCLC患者。分析和报告了放射治疗期间总肿瘤体积（GTV）的体积变化与结果之间的关系。中位放射剂量为59.4 Gy（中位分段剂量为1.8 Gy）。放射治疗前的中位GTV为74 cm^3，GTV缩减中位值为48%。与仅接受序贯化疗的患者相比，同时进行放化疗的患者具有更高的VRR（p = 0.05）。在整个队列中，没有发现任何体积参数与结果有关的相关预测因子。多变量分析表明，只有年龄对生存率产生影响，而预防性全脑放射治疗显著影响无进展生存期。与序贯化疗相比，同时进行化疗与更高的VRR相关。未检测到VRR对患者结果或生存率的显着影响。© 2023. 作者。

Several studies have reported the potential prognostic significance of tumor volume reduction ratio (VRR) induced by radiotherapy (RT) in patients with non-small-cell lung cancer. However, there are no data yet on the prognostic significance of volumetric shrinkage in patients with small-cell lung cancer (SCLC). This study aimed to demonstrate the correlation between tumor volume reduction ratio and treatment outcomes.The study included 61 patients with SCLC treated with fractionated RT of the primary tumor at our institution between 2013 and 2020. The relationship between volumetric changes in gross tumor volume (GTV) during radiotherapy and outcomes were analyzed and reported.The median radiation dose was 59.4 Gy (median fraction dose was 1.8 Gy). The median GTV before radiotherapy was 74 cm3, with a median GTV reduction of 48%. There was a higher VRR in patients receiving concurrent radiochemotherapy (p = 0.05). No volumetric parameters were identified as relevant predictors of outcome in the entire cohort. In multivariate analysis, only age had an impact on survival, while prophylactic whole-brain radiation influenced the progression-free survival significantly.Concurrent chemotherapy was associated with a higher VRR than sequential chemotherapy. No significant impact of VRR on patients' outcome or survival was detected.© 2023. The Author(s).